182 related articles for article (PubMed ID: 20001555)
1. Investigational drugs for hepatitis C.
Flisiak R; Parfieniuk A
Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
[TBL] [Abstract][Full Text] [Related]
2. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Chen J; Shi J; Xie WF; Zeng X; Lin Y
Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
[TBL] [Abstract][Full Text] [Related]
4. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Zeuzem S; Nelson DR; Marcellin P
Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C: therapeutic perspectives.
Cornberg M; Wedemeyer H; Manns MP
Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir.
Drugs R D; 2010; 10(3):203-10. PubMed ID: 20945949
[TBL] [Abstract][Full Text] [Related]
7. Adding telaprevir improves cure rate in patient with HCV infection.
AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
[No Abstract] [Full Text] [Related]
8. "Hepatitis C (HCV) treatment is not a "one size fits all".
Bukeirat FA; Bukeirat MM
W V Med J; 2012; 108(2):20, 22-4. PubMed ID: 22655431
[TBL] [Abstract][Full Text] [Related]
9. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
[TBL] [Abstract][Full Text] [Related]
10. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS; Aspinall E; Liew D; Thompson AJ; Hellard ME
Br J Clin Pharmacol; 2013 Apr; 75(4):931-43. PubMed ID: 22882367
[TBL] [Abstract][Full Text] [Related]
13. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
14. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir: a user's guide.
Kwo PY; Zhao R
Clin Liver Dis; 2011 Aug; 15(3):537-53. PubMed ID: 21867935
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of hepatitis C virus infection].
Zeuzem S
Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of individualized treatment for hepatitis C patients in the real world.
Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
[TBL] [Abstract][Full Text] [Related]
20. Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.
Rustgi VK
Expert Opin Drug Saf; 2010 Nov; 9(6):883-92. PubMed ID: 20553105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
